Paul Hastings LLP advised TD Cowen and the placement agents in connection with Harpoon Therapeutics’ offering. Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
